公开(公告)号：US20220273809A1

公开(公告)日：2022-09-01

申请号：US17628382

申请日：2020-07-17

Applicant: GENMAB A/S

Inventor： Maarten JANMAAT ,  Nora PENCHEVA ,  Esther Cornelia Wilhelmina BREIJ ,  Julia BOSHUIZEN ,  Daniel Simon PEEPER ,  Ulf FORSSMANN ,  Tahamtan AHMADI ,  Patricia Garrido CASTRO

IPC: A61K47/68 ,  A61P35/00 ,  A61K47/02

Abstract: The present invention relates to conjugates of antibodies and cytotoxic agents for use in treatment of cancer in combination with an inhibitor of PD-1 or PD-L1. The antibodies are directed against Axl.

公开(公告)号：US20210070869A1

公开(公告)日：2021-03-11

申请号：US17046199

申请日：2019-04-10

Applicant: GENMAB A/S

Inventor： Maarten JANMAAT ,  Esther BREIJ ,  Ulf FORSSMANN ,  Tahamtan AHMADI ,  Julia BOSHUIZEN ,  Daniel PEEPER ,  Nora PENCHEVA

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: The disclosure relates to anti-AXL antibodies, immunoconjugates, and compositions for treatment of cancer, which is resistant to or is predicted to be or become resistant to treatment with a programmed cell death-1/programmed cell death-1 ligand (PD-1/PD-L1) inhibitor.